Lymphoma | Topics

 
FDA Approves Crizotinib for Pediatric ALK+ ALCL Indication
January 14, 2021

Crizotinib—a tyrosine kinase inhibitor with activity against ALK, ROS1, and MET—was granted FDA approval for use in pediatric patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma.

Results Show Promising Efficacy in MCL With Next-Generation BTK Inhibitor LOXO-305
January 07, 2021

Investigators on the BRUIN trial reported impressive response rates across multiple B-cell malignancies with the use of the Bruton tyrosine kinase inhibitor LOXO-305, especially in those with heavily pretreated mantle cell lymphoma.

Armin Ghobadi, MD, on How to Interpret Preliminary Data in Patients with DLBCL
January 02, 2021

Ghobadi expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 ASH Annual Meeting.